Small Molecules Modulating Myosin II Cell Mechanics
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current compounds either inhibit or have limited ability to directly promote myosin II accumulation and recruitment to contractile structures, which is essential for modulating cell mechanics in therapeutic and tissue engineering applications, particularly in conditions like cancer and cardiovascular diseases.
Innovation Solution
Development of small molecules, such as 4-acetylphenyl-(3,4-dichlorophenyl) carbamate and 4-hydroxyacetophenone, that activate myosin II by promoting its assembly and recruitment to contractile structures, thereby modulating cell mechanics and treating disease conditions through systemic delivery.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing myosin II modulating compounds (inhibitors like Blebbistatin, BDM) are used, then myosin II activity is reduced, but the ability to directly promote myosin II accumulation and recruitment to contractile structures is limited
Solution Approach 1:
The invention changes the chemical parameters of myosin II modulating compounds by developing small molecules with specific chemical structures (compounds of formula I and II) that differ from existing inhibitors. These compounds have modified molecular properties that enable them to promote myosin II accumulation and recruitment while modulating its activity, resolving the limitation of existing compounds.
Solution Approach 2:
The small molecules of formula I and II act as intermediary compounds that mediate between the cellular environment and myosin II. These compounds serve as chemical messengers that specifically target and promote myosin II accumulation at contractile structures, a function that existing inhibitors cannot perform.
2Object-affected harmful factors
If myosin II activity is inhibited to treat disease conditions, then pathological processes may be reduced, but cell mechanics modulation capability is compromised
Solution Approach 1:
The invention introduces dynamic control of myosin II function by developing compounds that can promote myosin II accumulation and recruitment in a spatially and temporally regulated manner. This allows the system to adaptively modulate cell mechanics in response to disease conditions while maintaining the ability to treat pathology, rather than simply inhibiting myosin II activity.
Solution Approach 2:
The small molecules enable local quality control of myosin II by promoting its selective accumulation at specific contractile structures where needed. This localized action allows disease treatment while preserving or enhancing cell mechanics modulation capability at specific cellular locations, rather than globally inhibiting myosin II activity.
3Reliability
If small molecules are developed to directly promote myosin II accumulation, then therapeutic efficacy may be improved, but compound complexity increases
Solution Approach 1:
The invention employs small molecule compounds with relatively simple, well-defined chemical structures (formula I and II) rather than complex macromolecules. These small molecules serve as effective therapeutic agents that promote myosin II accumulation without requiring complex structural features, achieving therapeutic efficacy with simpler molecular designs.
Data Source
AI summary
Described are methods of treating or preventing a disease in a subject treatable by modulating cell mechanics. The method includes administering to a subject having or at risk for such a disease a pharmaceutical composition. comprising an agent selected from the group comprising a salt, solvate, or stereoisomer of compound (VIII) or its derivatives or a mixture of their constituents, where the compound has the formula: